TREATMENT
Review: varenicline, bupropion, and nicotine replacement therapies are effective for smoking cessation at 6 or 12 months
| The first 150 words of the full text of this article appear below. |
M J Eisenberg
Dr M J Eisenberg, Sir Mortimer B Davis Jewish General Hospital, Montreal, Quebec, Canada; mark.eisenberg@mcgill.ca
How do various pharmacotherapies compare for smoking cessation?
Studies selected compared any pharmacotherapy with placebo and reported biochemically validated measures of smoking abstinence. Trials that were unblinded or that evaluated reduced cigarette use, spontaneous cessation among smokers unwilling to quit, or smokers with chronic disease were excluded. Outcome was smoking cessation.
Medline, EMBASE/Excerpta Medica, Cochrane Library, and US Centers for Disease Control and Preventions Tobacco Information and Prevention database were searched for randomised controlled trials (RCTs). 69 RCTs (n = 32 908) met the selection criteria. Pharmacotherapies assessed were bupropion (16 RCTs), varenicline (13 RCTs), nicotine gum (22 RCTs), transdermal nicotine (30 RCTs), nicotine inhalers (4 RCTs), nicotine nasal spray (4 RCTs), and nicotine tablets (6 RCTs). Follow-up was at 6 or 12 months.
Meta-analysis showed that bupropion, varenicline, nicotine gum,
Centre for Nursing and Health Studies, Athabasca University, Athabasca, Alberta, Canada
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
